Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin
BJU International, 04/25/2012
Saito K et al. – C–reactive protein (CRP) kinetics is significantly associated with the prognosis and survival period of patients with advanced urothelial carcinoma (UC) treated by chemotherapy. Although larger confirmatory studies are warranted to validate the results, CRP can potentially be a useful biomarker for patients with advanced UC.